1. Amphiregulin is a potent mitogen for the vascular smooth muscle cell line, A7r5.
- Author
-
Kato M, Inazu T, Kawai Y, Masamura K, Yoshida M, Tanaka N, Miyamoto K, and Miyamori I
- Subjects
- Amphiregulin, Animals, Base Sequence, Cell Division drug effects, Cell Line, DNA biosynthesis, EGF Family of Proteins, Enzyme Activation drug effects, Epidermal Growth Factor genetics, ErbB Receptors genetics, Glycoproteins genetics, Glycoproteins metabolism, Intercellular Signaling Peptides and Proteins genetics, Intercellular Signaling Peptides and Proteins metabolism, MAP Kinase Signaling System, Mitogen-Activated Protein Kinases metabolism, Muscle, Smooth, Vascular cytology, Muscle, Smooth, Vascular metabolism, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins c-akt, RNA, Messenger genetics, RNA, Messenger metabolism, Rats, Thrombin pharmacology, Up-Regulation drug effects, Glycoproteins pharmacology, Intercellular Signaling Peptides and Proteins pharmacology, Mitogens pharmacology, Muscle, Smooth, Vascular drug effects, Protein Serine-Threonine Kinases
- Abstract
The regulation of amphiregulin, an epidermal growth factor (EGF) family member, and its effect on vascular smooth muscle cells (VSMC) were examined. Amphiregulin mRNA was upregulated by amphiregulin itself as well as alpha-thrombin. Amphiregulin caused an approximate 3-fold increase in DNA synthesis. Its effect on growth was compared with those of other mitogens, and was found to be approximately 3.5-, 2.4-, and 1.0-fold greater than those of endothelin-I (ET-I), alpha-thrombin, and platelet-derived growth factor-AB (PDGF-AB), respectively. As evidenced by Western blot analysis, amphiregulin stimulated the phosphorylation of p42/p44-mitogen-activated protein kinase (MAPK), p38-MAPK, c-Jun NH2-terminal protein kinase (JNK), and Akt/protein kinase B (PKB), respectively. By statistical analysis, the amphiregulin-induced growth effect was significantly decreased by the MAP kinase/ extracellular regulated kinase kinase-1 (MEK-1) inhibitor PD98059, p38-MAPK inhibitor SB203580, and phosphatidylinositol 3-kinase (PI-3 kinase) inhibitor wortmannin, respectively, but was not decreased by JNK inhibitor SP600125. These results suggest that amphiregulin is the most potent mitogen of the mitogens tested, and its growth effect is mediated at least in part through the p42/p44-MAPK, p38-MAPK, and PI-3 kinase-Akt/PKB pathways in VSMC.
- Published
- 2003
- Full Text
- View/download PDF